Author:
Oßwald Hartmut,Mühlbauer Bernd
Publisher
Springer Berlin Heidelberg
Reference19 articles.
1. Buggey J, Mentz RJ, Pitt B, Eisenstein EI, Anstrom KJ, Velazquez EJ, O’Connor CM (2015) A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 169:323–333
2. Bundesinstitut für Arzneimittel und Medizinprodukte (2019) Hydrochlorothiazid – Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hydrochlorothiazid.html
3. Jacob MS, Tang WH (2011) Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep 8:7–13
4. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551
5. Lachaine J, Beauchemin C, Ramos E (2011) Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin Pharmacol 20(11):4. https://doi.org/10.1186/1472-6904-11-4